Inc. (NYSE: BIO and BIO.B), a $8.49 billion market cap company known for its life science research and clinical diagnostics products, has announced plans to acquire Stilla Technologies, a developer of ...
Laboratories “announced that the company has entered into a binding offer to purchase all equity interests in Stilla ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback